T-1301 capsules test for advanced solid tumor cancers
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase study tests whether T-1301 capsules are safe and how well they can work in people with advanced solid tumors that can’t be treated with standard options. It focuses on side effects first, but results may help guide future treatment for advanced cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legally authorized representative) can sign informed consent and agree to study rules.
- You have an advanced solid tumor (including lymphoma) that has not responded to standard treatment, or standard treatment isn’t available or isn’t suitable for you.
- Your cancer can be measured or assessed by imaging/labs using standard RECIST v1.1 methods (and previously irradiated target lesions usually must show growth after radiation).
- You are expected to live at least 3 months and are age 20 or older.
- Your day-to-day function is good (ECOG 0 or 1) and you’ve recovered from prior treatment side effects to mild level (grade 1 or better, except hair loss).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests how safe T-1201 (an injection) is in people with advanced solid tumors that are not responding to standard treatment. It mainly looks at side effects and tolerability, and it may offer a treatment option if other options are no longer working.
This trial tests an experimental oral tablet (LIT-00814) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and to find the best dose.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests an experimental oral capsule (TQB3122) for safety and early signs of effectiveness in people with advanced solid tumors that have not responded to standard therapies. It is for patients who are relatively healthy and have specific cancer types like ovarian, breast, or prostate cancer.
This trial tests a new drug called T320, which is designed to target and kill cancer cells. It is for people with advanced solid tumors that have stopped responding to standard treatments or for whom no standard treatment exists.
This Phase 1 study tests a new oral capsule (TY-2699a) in people with advanced or metastatic solid tumors that have limited treatment options. It will look for the safest dose and whether the drug can shrink tumors, especially in certain genetic/biomarker patterns.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.